Novo Nordisk and Vivani Partner on Year-Long Implant
Novo Nordisk has entered into a research collaboration with medical technology firm Vivani Medical to develop a long-acting, implantable delivery system for semaglutide. The active ingredient in the blockbuster weight-loss drugs Wegovy and Ozempic, semaglutide is currently administered via weekly self-injections. This new partnership aims to create a tiny, subdermal implant capable of delivering the medication for up to one year, potentially addressing the adherence challenges inherent in the current regimen.
Engineering Sustained Release via NanoPortal
By providing a steady, consistent release of the drug into the bloodstream, the device aims to maintain therapeutic levels of the medication without the fluctuations often seen with periodic dosing.
Solving the Patient Adherence Hurdle
Weight-loss therapy with GLP-1 receptor agonists often requires long-term commitment. Clinical experience suggests that patient adherence—the ability to follow a prescribed regimen over months or years—is a critical factor in achieving and maintaining significant weight loss.
Market Positioning in a Competitive Landscape
For Novo Nordisk, this partnership represents a pivot toward extending the lifecycle of its flagship products. The agreement allows Novo Nordisk to leverage Vivani’s specialized delivery technology while maintaining its dominant position in the GLP-1 market.
Feasibility Testing and Regulatory Outlook
The collaboration is currently focused on feasibility testing. As of the latest updates, the companies have not provided a specific clinical trial timeline or a projected commercial launch date. The success of the project remains contingent on the results of initial preclinical evaluations, which will determine if the semaglutide molecule remains stable and effective when delivered via the NanoPortal system over such an extended duration.
Frequently Asked Questions
What is the NanoPortal platform?
Why is an implant better than an injection?
An implant is designed to improve adherence by removing the need for frequent self-injections, ensuring the patient receives a consistent dose without the risk of missing a weekly scheduled injection.
Is this treatment available to patients now?
No. The collaboration is currently in the research and evaluation stage, meaning the device is not yet approved for use or available to the public.
Worth a look